Performance evaluation of small-animal multipinhole μSPECT scanners for mouse imaging

Deleye, Steven; Holen, Roel Van; Verhaeghe, Jeroen; Vandenberghe, Stefaan; Stroobants, Sigrid; Staelens, Steven

doi:10.1007/s00259-012-2326-2

Cited by 75 publications

(62 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the experiment documenting heterogeneous treatment response only, the SPECT/CT scans at day 17 were obtained with both treatment groups. On the final day of the experiment, either 99m TcO 4 2 or 18 F-FDG was injected into animals, and animals were sacrificed 45 min later and organs treated as described above.…”

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

“…One cohort was treated with etoposide (67 mg/kg) (31) and the other with vehicle. On day 17, both cohorts were imaged with SPECT/CT ( 99m TcO 4 2 ) before a second dose of etoposide (67 mg/kg) or vehicle was administered. On day 19, both cohorts were subjected to PET/CT ( 18 F-FDG) imaging.…”

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

“…Mice were anesthetized with isoflurane, and 30 min after intravenous injection of 100 mL of a 99m TcO 4 2 solution (20 MBq) mice were imaged (30-min duration scans) using a nano-SPECT/CT instrument (Bioscan) without interruption of anesthesia. The PET/CT-based protocol for 18 The experimental schedules for the neoadjuvant chemotherapy experiments comparing the various imaging methods or tracers in etoposide-treated with untreated animals are outlined in the figure schematics.…”

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

“…The PET/CT-based protocol for 18 The experimental schedules for the neoadjuvant chemotherapy experiments comparing the various imaging methods or tracers in etoposide-treated with untreated animals are outlined in the figure schematics. For assessing the chemotherapy response, a first SPECT/CT scan ( 99m TcO 4 2 ) was obtained on day 9 after tumor inoculation, and animals were split into 2 cohorts on day 10 after tumor inoculation. One cohort was treated with etoposide (67 mg/kg) (31) and the other with vehicle.…”

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

“…NIS is a transmembrane glycoprotein mediating the active cellular concentration of iodide, driving this process via the symport of sodium ions using the sodium gradient maintained by the Na 1 /K 1 -adenosine triphosphatase (ATPase) (13). NIS can also transport other anions such as pertechnetate (TcO 4 2 ) (14) or tetrafluoroborate (15,16), allowing its exploitation in nuclear medicine for both SPECT or PET imaging. An advantage of NIS is that suitable tracers are widely available without the need for complex radiochemistry facilities.…”

mentioning

confidence: 99%

See 4 more Smart Citations

A Whole-Body Dual-Modality Radionuclide Optical Strategy for Preclinical Imaging of Metastasis and Heterogeneous Treatment Response in Different Microenvironments

et al. 2014

View full text Add to dashboard Cite

Imaging spontaneous cancer cell metastasis or heterogeneous tumor responses to drug treatment in vivo is difficult to achieve. The goal was to develop a new highly sensitive and reliable preclinical longitudinal in vivo imaging model for this purpose, thereby facilitating discovery and validation of anticancer therapies or molecular imaging agents. Methods: The strategy is based on breast cancer cells stably expressing the human sodium iodide symporter (NIS) fused to a red fluorescent protein, thereby permitting radionuclide and fluorescence imaging. Using whole-body nano-SPECT/CT with 99m TcO 4 − , we followed primary tumor growth and spontaneous metastasis in the presence or absence of etoposide treatment. NIS imaging was used to classify organs as small as individual lymph nodes (LNs) to be positive or negative for metastasis, and results were confirmed by confocal fluorescence microscopy. Etoposide treatment efficacy was proven by ex vivo anticaspase 3 staining and fluorescence microscopy. Results: In this preclinical model, we found that the NIS imaging strategy outperformed stateof-the-art 18 F-FDG imaging in its ability to detect small tumors (18.5-fold-better tumor-to-blood ratio) and metastases (LN, 3.6-fold) because of improved contrast in organs close to metastatic sites (12-and 8.5-fold-lower standardized uptake value in the heart and kidney, respectively). We applied the model to assess the treatment response to the neoadjuvant etoposide and found a consistent and reliable improvement in spontaneous metastasis detection. Importantly, we also found that tumor cells in different microenvironments responded in a heterogeneous manner to etoposide treatment, which could be determined only by the NIS-based strategy and not by 18 F-FDG imaging. Conclusion: We developed a new strategy for preclinical longitudinal in vivo cancer cell tracking with greater sensitivity and reliability than 18 F-FDG PET and applied it to track spontaneous and distant metastasis in the presence or absence of genotoxic stress therapy. Importantly, the model provides sufficient sensitivity and dynamic range to permit the reliable assessment of heterogeneous treatment responses in various microenvironments.

show abstract

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

Section: In Vivo Radionuclide Imaging and Analysis Of Biodistributionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

A Whole-Body Dual-Modality Radionuclide Optical Strategy for Preclinical Imaging of Metastasis and Heterogeneous Treatment Response in Different Microenvironments

et al. 2014

View full text Add to dashboard Cite

show abstract

Implementation of absolute quantification in small‐animal SPECT imaging: Phantom and animal studies

Gerdekoohi

Vosoughi

Tanha

et al. 2017

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposePresence of photon attenuation severely challenges quantitative accuracy in single‐photon emission computed tomography (SPECT) imaging. Subsequently, various attenuation correction methods have been developed to compensate for this degradation. The present study aims to implement an attenuation correction method and then to evaluate quantification accuracy of attenuation correction in small‐animal SPECT imaging.MethodsImages were reconstructed using an iterative reconstruction method based on the maximum‐likelihood expectation maximization (MLEM) algorithm including resolution recovery. This was implemented in our designed dedicated small‐animal SPECT (HiReSPECT) system. For accurate quantification, the voxel values were converted to activity concentration via a calculated calibration factor. An attenuation correction algorithm was developed based on the first‐order Chang's method. Both phantom study and experimental measurements with four rats were used in order to validate the proposed method.ResultsThe phantom experiments showed that the error of −15.5% in the estimation of activity concentration in a uniform region was reduced to +5.1% when attenuation correction was applied. For in vivo studies, the average quantitative error of −22.8 ± 6.3% (ranging from −31.2% to −14.8%) in the uncorrected images was reduced to +3.5 ± 6.7% (ranging from −6.7 to +9.8%) after applying attenuation correction.ConclusionThe results indicate that the proposed attenuation correction algorithm based on the first‐order Chang's method, as implemented in our dedicated small‐animal SPECT system, significantly improves accuracy of the quantitative analysis as well as the absolute quantification.

show abstract

Development of high‐resolution YAP(Ce) x‐ray camera for the imaging of astatine‐211(At‐211) in small animals

et al. 2020

View full text Add to dashboard Cite

Purpose Astatine‐211 (At‐211) is a promising alpha emitter for radionuclide therapy. High‐resolution in vivo imaging of At‐211 in small animals is needed for the development of At‐211 radiopharmaceuticals. For this purpose, we developed a low‐energy x‐ray camera using a thin YAlO3:Ce (YAP(Ce)) plate to image the low‐energy x rays (73–87 keV) from the daughter radionuclide of At‐211 (Po‐211). Method We optically coupled a 38 × 38 × 1‐mm YAP (Ce) plate to a position‐sensitive photomultiplier (PSPMT) to develop an imaging detector. A pinhole or a parallel hole collimator was attached to the imaging detector, and the performance was measured for 60‐keV gamma photons. With the developed x‐ray camera, we carried out imaging of a mouse that had been administered At‐211‐NaAt. Results The intrinsic spatial resolution of the YAP (Ce) x‐ray camera was approximately 1.2 mm FWHM, and the energy resolution was 22% FWHM. With a 5‐mm‐thick parallel hole collimator, the spatial resolution was 3.8 mm FWHM with a sensitivity of 8 × 10−4 at 10 mm, which is a typical distance from the surface of the collimator to a subject in mouse imaging. Using a 1‐mm diameter pinhole collimator, the spatial resolution was 1.8 mm FWHM with a sensitivity of 3.5 × 10−4 at 10 mm from the collimator. In the mouse images measured by the developed x‐ray camera, we could clearly observe that the At‐211 accumulated in the thyroid gland and the stomach of the mouse. Conclusion We concluded that the YAP (Ce) x‐ray camera is useful for in vivo imaging of At‐211.

show abstract

Performance evaluation of small-animal multipinhole μSPECT scanners for mouse imaging

Cited by 75 publications

References 49 publications

A Whole-Body Dual-Modality Radionuclide Optical Strategy for Preclinical Imaging of Metastasis and Heterogeneous Treatment Response in Different Microenvironments

A Whole-Body Dual-Modality Radionuclide Optical Strategy for Preclinical Imaging of Metastasis and Heterogeneous Treatment Response in Different Microenvironments

Implementation of absolute quantification in small‐animal SPECT imaging: Phantom and animal studies

Development of high‐resolution YAP(Ce) x‐ray camera for the imaging of astatine‐211(At‐211) in small animals

Contact Info

Product

Resources

About